Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site
type: MedicalStudy
description: A Phase II Trial of Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site
status: COMPLETED
study design: INTERVENTIONAL
phase: PHASE2
start date: 2004-04
end date: 2009-01
license: https://creativecommons.org/publicdomain/zero/1.0/
source: https://clinicaltrials.gov/study/NCT00193622
source organization: US National Library of Medicine
publisher: AI Analytics
sponsor: SCRI Development Innovations, LLC
study subject: Neoplasms, Unknown Primary
keywords: PHASE2
keywords: INTERVENTIONAL
keywords: COMPLETED
keywords: Neoplasms, Unknown Primary

AI Analytics
type: Organization